Evolent Health (EVH) Tops Q2 EPS by 5c, Rases Guidance

Evolent Health (NYSE: EVH) reported Q2 EPS of $0.10, $0.05 better than the analyst estimate of $0.05. Revenue for the quarter came in at $319.9 million versus the consensus estimate of $298.79 million.

GUIDANCE:

Evolent Health sees FY2022 revenue of $1.32-1.36 billion, versus the consensus of $1.22 billion.

Evolent Health sees Q3 2022 revenue of $343-363 million, versus the consensus of $312.7 million.

For earnings history and earnings-related data on Evolent Health (EVH) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Science Applications Int'l (SAIC) Tops Q2 EPS by 70c
• Why UBS thinks this European chipmaker is still undervalued despite its premium valuation